^
Association details:
| Biomarker: | HER-2 amplification |
|---|---|
| Cancer: | Gastric Cancer |
| Drug: | Keytruda (pembrolizumab) (PD1 inhibitor) + Margenza (margetuximab) (HER2 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Circulating Tumor DNA as a Predictive Biomarker for Clinical Outcomes With Margetuximab and Pembrolizumab in Pretreated HER2-Positive Gastric/ Gastroesophageal Adenocarcinoma
Published date:
04/25/2023
Excerpt:
ctDNA analysis was performed retrospectively using plasma samples collected at study entry from 86 patients participating in the phase 1/2 CP-MGAH22-05 study...Objective response rate (ORR) was significantly higher in evaluable ERBB2 amplification-positive vs - negative patients based on ctDNA analysis at study entry (37% vs 6%, respectively; P = .00094). ORR was 23% across all patients who were evaluable for response...Current ERBB2 status may be more effective than archival status at predicting clinical benefit from margetuximab plus pembrolizumab therapy.
DOI:
10.46883/2023.25920992
Trial ID:
Source:
Title:
Margetuximab (M) plus pembrolizumab (P) in ERBB2-amplified PD-L1+ gastroesophageal adenocarcinoma (GEA) post trastuzumab (T).
Published date:
06/01/2018
Excerpt:
Both ctDNA ERBB2 amp and PD-L1 positivity predicted response (24% vs. 0% [p = .0655] and 36% vs. 5% [p = .0367], respectively). In ctDNA ERBB2+/PD-L1+ pts, which were all GC, the ORR was 57% and DCR 86%....Our results suggest that M+P has encouraging preliminary activity in patients with advanced GC, and that biomarker selection based on ctDNA ERBB2 and PD-L1 could enrich for the responding population.
DOI:
10.1200/JCO.2018.36.15_suppl.4030
Trial ID:
Test:
